Keywords: lilly, alimta, gets, fda, advisers, backing, second-line

Lilly's Alimta gets FDA advisers' backing as second-line NSCLC therapy

Article | 02 August 2004

Print This

After a fairly short debate, the US Food and Drugs Administration'sOncologic Drugs Advisory Committee on July 27 voted to back approval ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in